Aptevo治疗学推进了癌症治疗,在临床试验中使用了有希望的双体抗体。 Aptevo Therapeutics advances cancer treatments with promising bispecific antibodies in clinical trials.

利用ADAPTIR和ADPTIR-FLEX的平台,Aptevo治疗机构正在开发创新的双体抗体,以应对具有攻击性的癌症。 Aptevo Therapeutics is developing innovative bispecific antibodies to tackle aggressive cancers, using its ADAPTIR® and ADAPTIR-FLEX® platforms. 其主要候选药物mipletamig在治疗急性髓性白血病方面显示出前景,而ALG.APV-527正在实体瘤的测试中. Its lead candidate, mipletamig, shows promise in treating acute myeloid leukemia, while ALG.APV-527 is being tested for solid tumors. 该公司的输油管包括5种双性抗体,预计到2030年,双性抗体将增长44%,使Aptevo成为癌症免疫疗法的主要参与者。 The company's pipeline includes five bispecific antibodies, and bispecifics are expected to grow by 44% by 2030, positioning Aptevo as a key player in cancer immunotherapy.

November 22, 2024

6 文章